What is it about?
High-dose prednisolone may not be superior to a low-dose regimen given over 6 weeks in improving the clinical, physiologic, and radiologic outcomes, or the health-related quality of life in symptomatic post-COVID-19 diffuse parenchymal lung abnormalities.
Featured Image
Why is it important?
In some patients, respiratory symptoms and imaging abnormalities persist after acute coronavirus disease 2019 (COVID-19) pneumonia. There are no randomised controlled trials on therapies for this condition. Our study is the first RCT for this condition, known as symptomatic post-COVID-19 diffuse parenchymal lung abnormalities (PC-DPLAS).
Perspectives
Most patients with mild symptoms and few residual abnormalities on chest CT scans after COVID-19 pneumonia recover spontaneously. We included patients with persistent and severe PC-DPLAS. For such patients, low-dose prednisolone may be a good and safe therapeutic choice to help in faster recovery.
Sahajal Dhooria
Postgraduate Institute of Medical Education and Research, Chandigarh, India
Read the Original
This page is a summary of: High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial), European Respiratory Journal, December 2021, European Respiratory Society (ERS),
DOI: 10.1183/13993003.02930-2021.
You can read the full text:
Contributors
The following have contributed to this page
